Advancing a clinically relevant perspective of the clonal nature of cancer

Abstract

Cancers frequently arise as a result of an acquired genomic instability and the subsequent clonal evolution of neoplastic cells with variable patterns of genetic aberrations. Thus, the presence and behaviors of distinct clonal populations in each patient's tumor may underlie multiple clinical phenotypes in cancers. We applied DNA content-based flow sorting to identify and isolate the nuclei of clonal populations from tumor biopsies, which was coupled with array CGH and targeted resequencing. The results produced high-definition genomic profiles of clonal populations from 40 pancreatic adenocarcinomas and a set of prostate adenocarcinomas, including serial biopsies from a patient who progressed to androgen-independent metastatic disease. The genomes of clonal populations were found to have patient-specific aberrations of clinical relevance. Furthermore, we identified genomic aberrations specific to therapeutically responsive and resistant clones arising during the evolution of androgen-independent metastatic prostate adenocarcinoma. We also distinguished divergent clonal populations within single biopsies and mapped aberrations in multiple aneuploid populations arising in primary and metastatic pancreatic adenocarcinoma. We propose that our high-definition analyses of the genomes of distinct clonal populations of cancer cells in patients in vivo can help guide diagnoses and tailor approaches to personalized treatment.clonal genomics | pancreatic cancer | prostate cancer

RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox—Point

“…Some of these diagnostics have led to predictive biomarkers for therapeutics, such as vemurafenib for melanoma harboring the V600E BRAF mutation (7). Molecular diagnostics have shown that clinically relevant differences exist in histologically identical tumors between patients, between tumors in the same patient, in the same tumor over time, and even in distinct clonal populations from the same tumor at the same time (8). When developing cancer therapeutics, it is reasonable to expect that different measures of efficacy may be needed for different molecular subtypes, due to differences in tumor biology and in the prognoses with available therapies.…”

Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor Heterogeneity

“…Debates as to whether these distinct subpopulations arise through clonal evolution (3) or via propagation of tumor-initiating cells with stem-like qualities (4) are alighting on the idea that the two concepts may be interlinked (5,6), and the cellular and genetic context determines which may predominate.…”

LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin

“…12, 13), and cervical cancer (14). Analysis of individual sectors of solid tumors, flow cytometry sorting (8,15,16), and single-cell sequencing (17) have identified distinct populations of tumor cells within individual patient samples. These studies provide insight into rates of genomic change in an evolving cancer and, importantly, help define genes associated with tumor progression and treatment failure (18).…”